stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Free cash flow
ImmunityBio, Inc.'s free cash flow for fiscal 2025 was −$308.8M, compared with −$398.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$288.1M. Over the past ten years it has ranged from −$436.9M (fiscal 2022) to −$27.5M (fiscal 2015); the current reading is higher than 36% of that period. ImmunityBio, Inc. ranks 563rd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$308.8M | — |
| FY2024 | −$398.1M | — |
| FY2023 | −$397.3M | — |
| FY2022 | −$436.9M | — |
| FY2021 | −$287.5M | — |
| FY2020 | −$173.4M | — |
| FY2019 | −$156.2M | — |
| FY2018 | −$76.1M | — |
| FY2017 | −$83.6M | — |
| FY2016 | −$45.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$70.0M | — |
| Mar 2026 | −$77.1M | — |
| Dec 2025 | −$71.3M | — |
| Sep 2025 | −$69.6M | — |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $310.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $130.6M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.4M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$168.7M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. | −$288.1M |
| CYTK Cytokinetics, Incorporated compare | −$588.6M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement